Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

BACKGROUND. The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. An ancillary study was conducted to evaluate the circulating tumor cell (CTC) c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sastre, Javier, Maestro, M. Luisa, Gómez-España, Auxiliadora, Rivera, Fernando, Valladares, Manuel, Massuti, Bartomeu, Benavides, Manuel, Gallén, Manuel, Marcuello, Eugenio, Abad, Albert, Arrivi, Antonio, Fernández-Martos, Carlos, González, Encarnación, Tabernero, Josep M., Vidaurreta, Marta, Aranda, Enrique, Díaz-Rubio, Eduardo
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2012
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399651/
https://ncbi.nlm.nih.gov/pubmed/22643538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0048
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars